{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Objective response rate per Response Assessment in Neuro-Oncology (RANO) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all disease sustained for at least four weeks; Partial Response (PR), \\>=50% decrease in the sum of the products of of the greatest perpendicular diameters of all measurable enhancing lesions, sustained for at least four weeks; Stable Disease (SD), \\< 50% decrease and \\< 25% increase in the sum of the products of of the greatest perpendicular diameters of all measurable enhancing lesions, sustained for at least 8 weeks; Progressive Disease (PD), \\>=25% increase in the sum of the products of of the greatest perpendicular diameters of all measurable enhancing lesions compared to the lowest sum recorded.","groups":[{"description":"Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.\n\nAntineoplaston therapy (Atengenal + Astugenal): Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).","id":"OG000","title":"Antineoplaston Therapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"12 months","title":"Number of Participants With Objective Response","type":"PRIMARY","unitOfMeasure":"Participants"}